Astrazeneca (AZN) Equity Ratio (2016 - 2025)

Astrazeneca has reported Equity Ratio over the past 11 years, most recently at 0.43 for Q4 2025.

For Q4 2025, Equity Ratio rose 8.71% year-over-year to 0.43; the TTM value through Dec 2025 reached 0.43, up 8.71%, while the annual FY2025 figure was 0.43, 8.71% up from the prior year.
Equity Ratio for Q4 2025 was 0.43 at Astrazeneca, up from 0.39 in the prior quarter.
Over five years, Equity Ratio peaked at 377.76 in Q4 2021 and troughed at 0.38 in Q4 2022.
A 5-year average of 100.82 and a median of 0.43 in 2025 define the central range for Equity Ratio.
Biggest five-year swings in Equity Ratio: skyrocketed 123544.63% in 2021 and later plummeted 99.9% in 2022.
Year by year, Equity Ratio stood at 377.76 in 2021, then crashed by 99.9% to 0.38 in 2022, then skyrocketed by 32478.7% to 125.13 in 2023, then tumbled by 99.69% to 0.39 in 2024, then grew by 8.71% to 0.43 in 2025.
Business Quant data shows Equity Ratio for AZN at 0.43 in Q4 2025, 0.39 in Q4 2024, and 125.13 in Q4 2023.

Peer Comparison